{
    "clinical_study": {
        "@rank": "4769", 
        "arm_group": [
            {
                "arm_group_label": "DA-3002 Treatment group", 
                "arm_group_type": "Experimental", 
                "description": "1.11 IU(0.37mg)/kg bodyweight of DA-3002 per week given by subcutaneous injections (six or seven times per week)"
            }, 
            {
                "arm_group_label": "Non-treatment control group", 
                "arm_group_type": "No Intervention", 
                "description": "Height be measured with no treatment"
            }
        ], 
        "brief_summary": {
            "textblock": "Growth hormone therapy will improve the height of idiopathic short statured children.\n      DA-3002(Recombinant Human Growth hormone)treated group for 26 weeks, will be compared to\n      non-treatment group in efficacy and safety."
        }, 
        "brief_title": "Idiopathic Short Stature Study", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Idiopathic Short Stature", 
        "condition_browse": {
            "mesh_term": "Dwarfism"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Chronological Age \u2265 4\n\n          -  Bone Age <11 (for girls) and <13 (for boys)\n\n          -  Height <3rd percentile for age\n\n          -  normal thyroid function\n\n        Exclusion Criteria:\n\n          -  endocrine and/or metabolic disorders\n\n          -  growth failure caused by other disorders\n\n          -  previous use of drugs that could interfere with Growth Hormone treatment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "13 Years", 
            "minimum_age": "4 Years"
        }, 
        "enrollment": {
            "#text": "70", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01786902", 
            "org_study_id": "DA3002_ISS_III"
        }, 
        "intervention": {
            "arm_group_label": "DA-3002 Treatment group", 
            "intervention_name": "DA-3002", 
            "intervention_type": "Drug", 
            "other_name": "Recombinant Human Growth Hormone"
        }, 
        "intervention_browse": {
            "mesh_term": "Hormones"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "growth hormone", 
        "lastchanged_date": "August 12, 2013", 
        "number_of_arms": "2", 
        "official_title": "Open, Multi-Center, Controlled, Randomized Phase III Clinical Trial to Evaluate the Efficacy and Safety of DA-3002(Recombinant Humn Growth Hormone)Treatment in Children With Idiopathic Short Stature", 
        "other_outcome": {
            "measure": "The change of antibodies to growth hormone", 
            "safety_issue": "Yes", 
            "time_frame": "26 weeks"
        }, 
        "overall_official": [
            {
                "affiliation": "Asan Medical Center", 
                "last_name": "Hanwook Yoo, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Seoul St. Mary's Hospital", 
                "last_name": "Byungkyu Suh, MD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Kyungpook National University", 
                "last_name": "Cheolwoo Ko, MD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Korea University Anam Hospitial", 
                "last_name": "Keehyoung Lee, MD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Samsung Medical Center", 
                "last_name": "Dongkyu Jin, MD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Seoul National University Hospital", 
                "last_name": "Choongho Shin, MD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Aju University Hospital", 
                "last_name": "Jinsoon Hwang, MD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Severance Children's Hospital Yonsei University", 
                "last_name": "Hoseong Kim, MD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Pusan University Hospital", 
                "last_name": "Wooyoung Jeong, MD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Chonnam National University Hospital", 
                "last_name": "Chanjong Kim, MD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Chungbuk National University", 
                "last_name": "Heonsuk Han, MD", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "South Korea : Korea Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The difference of annualized height velocity between treatment group and non-treatment group after 26 weeks", 
            "safety_issue": "No", 
            "time_frame": "26 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01786902"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Difference of Height Standard Deviation Score between treatment and non-treatment group after 26 weeks", 
            "safety_issue": "No", 
            "time_frame": "26 weeks"
        }, 
        "source": "Dong-A Pharmaceutical Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Dong-A Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}